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Summary

The antihyperlipidemic activity of Spirulina platensis (family:
Oscillatoriacae, cynobacteria/blue green algae) was evaluated
in isoproterenol-induced hyperlipidemic rats. In the present
study, Spirulina platensis powder suspended in water was
administered orally to rats for 21 days at the dose of 450
mg/kg/day followed by subcutaneous administration of
isoproterenol (200 mg/kg/day for 2 days). Isoproterenol, a
synthetic catecholamine and β-adrenergic agonist has reported
to cause oxidative stress with subsequent increase in serum
lipid profile after subcutaneous administration.
The clinical biochemistry parameters like serum cholesterol,
triglycerides, HDL-cholesterol, atherogenic index, VLDL and
LDL cholesterol of the rats were determined for the evaluation
of antihyperlipidemic activity of Spirulina platensis. The
minimum alteration in clinical biochemistry parameters were
observed in Spirulina platensis treated animals as compared to
control animals indicating its antihyperlipidemic potential.
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Cardiovascular disorder has become the leading cause of death worldwide.
Epidemiological studies established a direct relationship of serum cholesterol and
coronary artery disease [1]. Hyperlipidemia is characterized by increased triglyceride-rich
lipoproteins, postprandial lipemia and decreased high-density lipoprotein (HDL)
cholesterol [2]. The efforts of lowering lipid levels in different studies indicated lower
morbidity and mortality in coronary heart disease which commensurate with reduction of
serum cholesterol [3].
Spirulina platensis (family: Oscillatoriacae) is a blue green algae comprising of vital
nutrients such as proteins, lipids and carbohydrates. It also contains essential elements
like Zinc, Magnesium, Manganese, Selenium, and some vitamins like β–carotene,
riboflavin, cyanocobalamine, α-tocopherol and α–linoleic acid. All these minerals,
nutrients and vitamins promote physical health, improve the non specific resistance of the
body, prevent the disturbances in homeostasis of the human system and promote revival
of physiological functions after debilitating diseases. It also exhibits antioxidant activity
[4, 5].
Isoproterenol, a synthetic catecholamine and β-adrenergic agonist has reported to cause
oxidative stress in the myocardium, resulting in infarct-like necrosis of heart muscle [6].
The pathophysiological changes following isoproterenol administration were compared to
human myocardial infarction [7].
Mathew et al, reported an altered lipid metabolism in myocardial necrosis following
isoproterenol administration [8]. The present study investigated the beneficial effect of
Spirulina platensis pretreatment in isoproterenol-induced hyperlipidemia in rats.

Methods

Plant product
Spirulina platensis was received as a gift sample in the form of spray dried powder from
M/s Parry Nutraceuticals, Ltd., Chennai, Tamilnadu, India. It has also other constituents
like pigments, vitamins and minerals.
The composition of the spray dried green powder of Spirulina platensis (Constituent/100
g) was as follows:
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Major constituents
Proteins: 60-69%
Fats: 6.7%
Crude fibres: 9.3%
Carbohydrates: 16%
Vitamins
Beta carotene: 3,20,000 I.U. Biotin: 0.22 mg
Cynocobalamine: 65.7 mg
Folic acid: 17.6 mg
Inositol: 0.018 mg
Niacin: 6.69 mg
Pyridoxin HCl: 0.39 mg
Riboflavin: 1.78 mg
Thiamine: 0.118 mg
Tocoferol (E): 0.733 I.U.
Minerals
Calcium: 131.5 mg
Iron: 58 mg
Sodium: 41.2 mg
Chloride: 440 mg
Magnesium: 191 mg
Zinc: 3.9 mg
Potassium: 1540 mg

Animals
Wistar albino rats of either sex (180-220 g) randomly bred in the registered animal house
facility of M.U.I.C.T., Mumbai, India were used for the study. The animals were housed
in standard environmental conditions of temperature (22±5 0C) and humidity (55±15 %)
with 12-h light-dark cycles. They were fed with commercial pelleted feed (M/s D. S.
Trading Co., Mumbai) and water ad libitum. All the procedures were performed in
accordance with the Institutional Animal Ethics Committee (IAEC) constituted as per the
directions of the Committee for the Purpose of Control and Supervision of Experiments
on Animals (CPCSEA) under Ministry of Animal Welfare Division, Government of India,
New Delhi, India [9]. The Institutional Animal Ethics Committee of M.U.I.C.T.,
Department of Pharmaceutical Sciences, approved the experimental protocol.

Experimental Design
The rats were divided into two groups of 12 animals each. Group 1 was treated as a
control and received purified water (10 ml/kg/day for 21 days) by oral route. Group 2
received suspension of Spirulina platensis powder in water at the dose of 450 mg/kg/day,
orally for a period of 21 days. At the end of 21 days, the rats from group 1 were divided
in subgroups I and II and animals of group 2 were divided in subgroups III and IV. The
treatments received in different groups were as follows.
I) Control group II) Control with Isoproterenol (200 mg/kg, s.c.), III) Spirulina platensis
(450 mg/kg) and IV) Spirulina platensis (450 mg/kg) with isoproterenol (200 mg/kg, s.c.)

Induction of Hyperlipidemia
To induce hyperlipedemia, animals from group II and IV received Isoproterenol (Sigma,
USA, 200 mg/kg, s.c.) twice at an interval of 24 hours [10].
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Blood Collection
After the experimental period (i.e. 24 hour after second administration of isoproterenol)
the blood was collected through retro-orbital plexus under light ether anesthesia in the
eppendorf tubes. The serum was separated by spinning in temperature-controlled
centrifuge (Superspin R-V/FM, Plasto Crafts, India). The serum from group I and III were
also separated similarly.

Serum Lipid profile
The serum cholesterol, triglycerides and HDL cholesterol were estimated in serum by
using kits procured from Merck Ecoline®, Mumbai, India. The serum total lipids were
determined by using commercially available kit manufactured by Span Diagnostics Ltd.,
Sachin, Surat, India. The LDL cholesterol and VLDL were calculated using Friedwalds
formula [11] and method of Godkar [12].
VLDL = Triglyerides/5
LDL cholesterol = Cholesterol – (HDL Cholesterol + VLDL/5)

Statistical analysis
The data were expressed as the mean ± S.E.M. obtained from the number of experiments
(n=6). One-way ANOVA with Tukey’s test was performed using GraphPad Prism
version 4.00 for Windows, GraphPad Software [13], San Diego California USA,
www.graphpad.com. The statistical significance was accepted at p<0.05.

Results

Effect of Spirulina platensis on cholesterol, triglycerides and total lipids
The serum concentration of cholesterol, triglycerides and total lipids was decreased
significantly (P<0.01) in Spirulina platensis pretreated (21 days) groups as presented in
table 1 compared to isoproterenol treated control.
Table 1 Effect of Spirulina platensis pretreatment (450 mg/kg, p.o.) on cholesterol,
triglycerides and total lipids.
Groups

Treatment

Cholesterol
(mg/dl)

Triglycerides
(mg/dl)

Total Lipids
(mg/dl)

I

Control
103.4±6.26
65.8±4.91
451.8±14.38
Isoproterenol control (200
II
135.0±4.63
114.1±5.43
485.6±13.85
mg/kg s.c.)
III
S. platensis (450 mg/kg, p.o.)
104.5±6.32 a
61.3±4.87 b
452.0±14.32
S. platensis (450 mg/kg, p.o.) +
IV
109.4±5.21 a
82.2±5.16 a
455.6±13.37 b
isoproterenol (200 mg/kg, s.c.)
Values are expressed as mean ± S.E.M. from 6 animals. Statistical analysis by one-way
ANOVA followed by Tukey’s test using Graphpad Prism software; aP < 0.01 and bP
<0.05 compared to isoproterenol control (200 mg/kg, s.c.).
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Effect of Spirulina platensis on LDL and HDL cholesterol and LDLc/HDLc risk
factor
The serum concentration of LDL cholesterol was elevated due to isoproterenol
administration in group II but it was not increased in III and IV as the Spirulina platensis
pretreated group. HDL cholesterol was also increased significantly (P<0.01) in Spirulina
platensis treated groups compared to isoproterenol control. The increase in HDL
cholesterol and decrease in LDL cholesterol results in reduction of cardiovascular risk
factor LDLc/HDLc in Spirulina platensis treated group compared to isoproterenol
control. The results are mentioned in table 2.
Table 2 Effect of Spirulina platensis pretreatment (450 mg/kg, p.o.) on HDL cholesterol,
LDL cholesterol, and LDLc/HDLc risk factor.
HDL
LDL
Risk factor
Groups
Treatment
cholesterol
cholesterol
LDLc/HDLc
(mg/dl)
(mg/dl)
I
Control
20.6±1.45
34.6±1.45
1.7±0.19
Isoproterenol control (200
14.2±1.46
36.4±1.69
2.6±0.26
mg/kg s.c.)
44.2 ±1.25 a
2.0±0.13
III
S. platensis (450 mg/kg)
22.2 ±1.23 a
S. platensis (450 mg/kg) +
IV
35.1±1.55 b
1.6±0.15 b
21.5±1.38 a
isoproterenol (200 mg/kg, s.c.)
Values are expressed as mean ± S.E.M. from 6 animals. Statistical analysis by one-way
ANOVA followed by Tukey’s test using Graphpad Prism software; aP < 0.01 and bP
<0.05 compared to isoproterenol control (200 mg/kg, s.c.).
II

Effect of Spirulina platensis on atherogenic index and VLDL fraction
The calculated VLDL fraction of lipid profile was lessen in Spirulina platensis treated
group subsequently the atherogenic potential also reduced significantly (p<0.01)
compared to isoproterenol control. The atherogenic index was calculated from the
following formula,
Cholesterol – HDL Cholesterol
Atherogenic Index [14] =
HDL Cholesterol
Table 3 Effect of Spirulina platensis pretreatment (450mg/kg, p.o.) on atherogenic index
and VLDL fraction.
Groups

Experimental Groups

Atherogenic
index

VLDL fraction
(mg/dl)

I

Control

4.2±0.57

13.1±0.58

II

Isoproterenol control (200 mg/kg s.c.)

7.4±0.99

22.8±0.68

S. platensis (450 mg/kg)
3.8±0.30 a
12.2±0.57 b
S. platensis (450 mg/kg) + isoproterenol
16.4±0.63 b
IV
4.2±0.37 a
(200 mg/kg s.c.)
Values are expressed as mean ± S.E.M. from 6 animals. Statistical analysis by one-way
ANOVA followed by Tukey’s test using Graphpad Prism software; aP < 0.01 and
b
P<0.05 compared to isoproterenol control (200 mg/kg, s.c.).
III
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Discussion
The levels of lipid profile and atherosclerosis risk is reduced in animals pretreated with
Spirulina platensis for 21 days are presented in table 1, 2 and 3. Spirulina Platensis
pretreatment and subsequent exposure to isoproterenol results in minimum alteration of
cholesterol, triglycerides, Low and high-density lipoprotein.
In isoproterenol administered rat group II, cholesterol and triglycerides, LDL and VLDL
fractions increased significantly with a decrease in HDL cholesterol. In groups IV rats
(Spirulina platensis + isoproterenol treated) the alterations in the levels of cholesterol and
triglycerides, LDL, HDL and VLDL fractions were minimum. HDL alters the balance of
unesterified cholesterol between plasma and cells by increasing its utilization in lecithin
cholesterol acyl transferase system to form cholesterol ester, which moves rapidly back
into cells [15].
The twice isoproterenol (200 mg/kg s.c.) administration results in significant increase in
serum cholesterol, triglycerides, total lipids and LDL cholesterol. Increased levels of
circulating cholesterol fractions and its accumulation in heart tissue are well associated
with cardiovascular damage [8]. Hypertriglyceridemia was seen in isoproterenol-treated
rats, condition observed in ischemic heart disease, and is due to a decrease in the activity
of lipoprotein lipase in the myocardium resulting in decreased uptake of triglycerides
from circulation [9]. The administration of isoproterenol mainly raised LDL cholesterol
and decreased HDL cholesterol level in serum [16].
Spirulina platensis affect on lipoprotein lipase activity and hepatic triglyceride lipase
activities in post-heparin plasma were studied in fructose-induced hyperlipidemic rats
[17]. The presence of novel protein C-phycocyanin (C-PC) present in Spirulina platensis
may involve in the inhibition of both jejunal cholesterol absorption and ileal bile acid
reabsorption [18]. It is found that the aqueous extract of Spirulina platensis may inhibit
the intestinal absorption of dietary fat by inhibiting pancreatic lipase activity [19]. C-PC,
one of the major phycobiliproteins of Spirulina platensis (a blue-green alga), which is
involved in first increased cyclic GMP/VASP Ser157 phosphorylation and subsequently
inhibits protein kinase C activity, resulting in inhibition of both P47 phosphorylation and
intracellular Ca2+ mobilization, and secondly may inhibit free radicals (such as hydroxyl
radicals) released from activated platelets, which ultimately inhibits platelet aggregation.
This maintains blood homeostasis in experimental animals [20].
The multicomponent spray dried powder of marine algae, Spirulina platensis contains
substantial amount of gamma-linolenic acid (GLA) may prevent accumulation of
cholesterol and is also established clinically [21]. One of the earlier studies on the
reduction of serum cholesterol by Spirulina was that done on rats by Devi and
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Venkataraman. Since then several workers have confirmed antihyperlipidemic studies
involving animals and humans [22].
Spirulina platensis has been proved beneficial in treatments like hepatoprotective effect
in anti-tubercular drug induced hepatotoxicity in rats [23]. The effect of Spirulina
platensis
powder
was
successfully
evaluated
for
cholesterol-induced
hypercholesterolemia by Japanese scientist in rats [24]. The spray-dried powder
contributes to the treatment in hyperlipidemic condition and in combination of many
important medicinal plants it can be recommended for the wide use.
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